Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Autistic Disorder
Interventions: D-cycloserine, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Insomnia Disorder
Interventions: lemborexant, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 42
States / cities: Chandler, Arizona • Rogers, Arkansas • Beverly Hills, California + 35 more

Conditions: Tooth Loss
Interventions: allograft + x-link collagen membrane, xenograft + non-x-link collagen; Device
Lead sponsor: McGuire Institute; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions: ABI-1968; Drug
Lead sponsor: Antiva Biosciences; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 6
States / cities: Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more

Conditions: Obstructive Sleep Apnea, Snoring
Interventions: Adenotonsillectomy (AT) - removal of adenoids and tonsils, Watchful Waiting; Procedure · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 5 Years to 9 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Conditions: Major Depressive Disorder
Interventions: Cranial Electrotherapy Stimulation, Sham Cranial Electrotherapy Stimulation; Device
Lead sponsor: Electromedical Products International, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Forest, Virginia

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Octreotide LAR Depot, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more

Conditions: Acute Ischemic Stroke
Interventions: NTS-104 TRIS, Placebo; Drug
Lead sponsor: NeuroTrauma Sciences, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions: Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention, Usual Care; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions: Vancomycin Oral Capsule, Placebo Oral Capsule; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Systemic Sclerosis (SSc)
Interventions: Diet 1: Restriction of fermentable carbohydrates, Diet 2: Elimination of foods harmful to gut barrier and microbiome, Diet 3: Regular meal patterns, soluble fiber, and portion control; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol/glycopyrrolate, indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Peoria, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more

Conditions: Geographic Atrophy
Interventions: FCFD4514S, sham; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years to 89 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 30
States / cities: Tucson, Arizona • Beverly Hills, California • San Francisco, California + 26 more

Conditions: Bariatric Surgery Candidate, Pain, Postoperative, Nausea and Vomiting, Postoperative, Opioid Use
Interventions: Intraoperative autonomic neural blockade (ANB), Laparoscopic Standard of Care Abdominal Wall Block; Procedure
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Abortion in First Trimester, Pain, Procedural, Opioid Use
Interventions: Ketamine, Fentanyl; Drug
Lead sponsor: University of Washington; Other
Eligibility: 14 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Renton, Washington

Conditions: Dietary Habits
Interventions: Semi-controlled dietary intervention - Western, Semi-controlled dietary intervention - MiniMed; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 69 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 6 more

Conditions: Major Depressive Disorder
Interventions: Quetiapine fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 37
States / cities: Little Rock, Arkansas • Newport Beach, California • Northridge, California + 34 more

Conditions: Glucose Intolerance
Interventions: Active, Placebo; Dietary Supplement
Lead sponsor: The Center for Applied Health Sciences, LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Sickle Cell Disease
Interventions: ICA-17043; Drug
Lead sponsor: Icagen; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 42
States / cities: Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more

Conditions: Hypertension
Interventions: Active Outreach to Patients and Providers; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 79 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 257
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more

Conditions: Diabetic Foot Ulcers
Interventions: MEBO Wound Ointment, Standard of Care (sterile saline moistened gauze); Drug · Procedure
Lead sponsor: Skingenix, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Search by objective public record fields.

Safety and Effectiveness of D-Cycloserine in Children With Autism

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

An RCT Comparing Xenograft and Allograft for Ridge Preservation

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

Childhood Adenotonsillectomy Study for Children With OSAS

Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults

Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Systemic Sclerosis DIet for GastrointESTinal Symptoms

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

Autonomic Neural Blockade in Bariatric Surgery

Ketamine Versus Fentanyl for Surgical Abortions

Metabolomics Initiative: Mediterranean-amplified vs Habitual Western Diet on Food Signatures, Health, and Microbiome

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder

Effects of a Dietary Supplement Containing Salacia Extract, Citrus Bioflavonoids, and Trivalent Chromium on Markers of Glucose Control

A Stratified Sickle Event Randomized Trial (ASSERT)

Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)